Scolaris Content Display Scolaris Content Display

Anticonvulsants for cocaine dependence

Appendices

Appendix 1. CENTRAL search

  1. MeSH descriptor: [Cocaine‐Related Disorders] explode all trees

  2. (cocaine* or crack):ti,ab,kw (Word variations have been searched)

  3. #1 or #2

  4. (anticonvulsant* or carbamazepine or clorazepate or clobazam or clonazepam or chlordiazepoxide or divalproex or ethosuximide or ethosuximide or ethotoin or felbamate or fosphenytoin or gabapentin or lignocaine or lamotrigine or levetiracetam or lidocaine or hydantoins or levetiracetam or methsuximide or oxcarbazepine or paraldehyde or phenacemide or phenytoin or pregabalin or primidone or succinimide or tiagabine or topiramate or valproate or vigabatrin or zonisamide):ti,ab,kw (Word variations have been searched)

  5. ACTH:ti,ab

  6. #4 or #5

  7. #3 and #6

Appendix 2. MEDLINE search strategy

  1. Cocaine‐Related Disorders [Mesh]

  2. ((cocaine*[tiab]) AND (abuse*[tiab] OR addict*[tiab] OR dependen*[tiab]))

  3. #1 OR #2

  4. "Anticonvulsants"[Mesh]

  5. anticonvulsant* [tiab]

  6. ACTH[tiab]

  7. carbamazepine OR clorazepate OR clobazam OR clonazepam OR chlordiazepoxide OR divalproex OR ethosuximide OR ethosuximide OR ethotoin OR felbamate OR fosphenytoin OR gabapentin OR lignocaine OR lamotrigine OR levetiracetam OR lidocaine OR hydantoins OR levetiracetam OR methsuximide OR oxcarbazepine OR paraldehyde OR phenacemide OR phenytoin OR pregabalin OR primidone OR succinimide OR tiagabine OR topiramate OR valproate OR vigabatrin OR zonisamide

  8. #4 OR #5 OR #6 OR #7

  9. randomized controlled trial [pt])

  10. controlled clinical trial [pt])

  11. randomized [tiab])

  12. drug therapy [sh])

  13. randomly [tiab])

  14. trial [tiab])

  15. groups [tiab])

  16. placebo [tiab]

  17. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16

  18. animals [mh] NOT humans [mh]

  19. #17 NOT #18

  20. #3 AND #8 AND #19

Appendix 3. EMBASE search strategy

  1. 'cocaine dependence'/exp

  2. (cocaine:ab,ti AND (abus*:ab,ti OR dependen*:ab,ti OR disorder*:ab,ti OR addict*:ab,ti))

  3. 'cocaine'/exp OR 'cocaine derivative'/exp AND

  4. #1 OR #2 OR #3

  5. 'anticonvulsive agent'/exp OR

  6. acth:ab,ti OR anticonvulsant*:ab,ti OR carbamazepine:ab,ti OR clorazepate:ab,ti OR clobazam:ab,ti OR clonazepam:ab,ti OR chlordiazepoxide:ab,ti OR divalproex:ab,ti OR ethosuximide:ab,ti OR ethotoin:ab,ti OR felbamate:ab,ti OR fosphenytoin:ab,ti OR gabapentin:ab,ti OR lignocaine:ab,ti OR lamotrigine:ab,ti OR lidocaine:ab,ti OR hydantoins:ab,ti OR levetiracetam:ab,ti OR methsuximide:ab,ti OR oxcarbazepine:ab,ti OR paraldehyde:ab,ti OR phenacemide:ab,ti OR phenytoin:ab,ti OR pregabalin:ab,ti OR primidone:ab,ti OR succinimide:ab,ti OR tiagabine:ab,ti OR topiramate:ab,ti OR valproate:ab,ti OR vigabatrin:ab,ti OR zonisamide:ab,ti AND

  7. #5 OR #6

  8. 'randomized controlled trial'/exp

  9. 'crossover procedure'/exp

  10. 'double blind procedure'/exp

  11. 'single blind procedure'/exp

  12. 'controlled clinical trial'/exp

  13. 'clinical trial'/exp

  14. placebo:ab,ti OR 'double blind':ab,ti OR 'single blind':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti)

  15. #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14

  16. #4 AND #7 AND #15

Appendix 4. CINAHL search strategy

  1. (MH "Substance Use Disorders+")

  2. TX((cocaine) AND (abuse* OR dependen* OR addict* OR disorder*))

  3. TI cocaine* OR AB cocaine* OR MH cocaine

  4. S1 OR S2 OR S3

  5. (MH "Anticonvulsants+")

  6. TI (carbamazepine OR clorazepate OR clobazam OR clonazepam OR chlordiazepoxide OR divalproex OR ethosuximide OR ethosuximide OR ethotoin OR felbamate OR fosphenytoin OR gabapentin OR lignocaine OR lamotrigine OR levetiracetam OR lidocaine OR hydantoins OR levetiracetam OR methsuximide OR oxcarbazepine OR paraldehyde OR phenacemide OR phenytoin OR pregabalin OR primidone OR succinimide OR tiagabine OR topiramate OR valproate OR vigabatrin OR zonisamide)

  7. AB (carbamazepine OR clorazepate OR clobazam OR clonazepam OR chlordiazepoxide OR divalproex OR ethosuximide OR ethosuximide OR ethotoin OR felbamate OR fosphenytoin OR gabapentin OR lignocaine OR lamotrigine OR levetiracetam OR lidocaine OR hydantoins OR levetiracetam OR methsuximide OR oxcarbazepine OR paraldehyde OR phenacemide OR phenytoin OR pregabalin OR primidone OR succinimide OR tiagabine OR topiramate OR valproate OR vigabatrin OR zonisamide)

  8. TI anticonvulsant* OR AB anticonvulsant*

  9. TI ACTH OR AB ACTH

  10. S5 OR S6 OR S7 OR S8 OR S9

  11. MH "Clinical Trials+"

  12. PT Clinical trial

  13. TI clinic* N1 trial* or AB clinic* N1 trial*

  14. TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )

  15. AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )

  16. TI randomi?ed control* trial* or AB randomi?ed control* trial*

  17. MH "Random Assignment"

  18. TI random* allocat* or AB random* allocat*

  19. MH "Placebos"

  20. TI placebo* or AB placebo*

  21. MH "Quantitative Studies"

  22. S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21

  23. S4 AND S10 AND S22

Appendix 5. Web of Science search strategy

  1. TS=((( cocaine* OR crack) AND (abuse* OR depend* OR addict* OR disorder* OR detox* OR withdraw* OR abstinen* OR abstain*)))

  2. TS=(anticonvulsant* OR carbamazepine OR clorazepate OR clobazam OR clonazepam OR chlordiazepoxide OR divalproex OR ethosuximide OR ethosuximide OR ethotoin OR felbamate OR fosphenytoin OR gabapentin OR lignocaine OR lamotrigine OR levetiracetam OR lidocaine OR hydantoins OR levetiracetam OR methsuximide OR oxcarbazepine OR paraldehyde OR phenacemide OR phenytoin OR pregabalin OR primidone OR succinimide OR tiagabine OR topiramate OR valproate OR vigabatrin OR zonisamide)

  3. TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=follow‐up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)

  4. #1 AND #2 AND #3

Indexes=SCI‐EXPANDED, SSCI, A&HCI Timespan=All years

Appendix 6. Criteria for risk of bias assessment

Item

Judgment

Description

1. Random sequence generation (selection bias)

Low risk

Investigators describe a random component in the sequence generation process such as random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation

High risk

Investigators describe a non‐random component in the sequence generation process such as odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or a series of tests; availability of the intervention

Unclear risk

Insufficient information about the sequence generation process to permit judgement of low or high risk

2. Allocation concealment (selection bias)

Low risk

Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled, randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes

High risk

Investigators enrolling participants could possibly foresee assignments because one of the following methods was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or were not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure

Unclear risk

Insufficient information to permit judgement of low or high risk. This is usually the case if the method of concealment is not described or is not described in sufficient detail to allow a definitive judgement

3. Blinding of participants and providers (performance bias);

objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding

Blinding of participants and key study personnel ensured, and unlikely that blinding could have been broken

High risk

No blinding or incomplete blinding, and outcome is likely to be influenced by lack of blinding

Blinding of key study participants and personnel attempted, but likely that blinding could have been broken, and the outcome is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

4. Blinding of participants and providers (performance bias);

subjective outcomes

Low risk

Blinding of participants and providers and unlikely that blinding could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding

Blinding of key study participants and personnel attempted, but likely that blinding could have been broken, and the outcome is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

5. Blinding of outcome assessor (detection bias);

objective outcomes

Low risk

No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding

Blinding of outcome assessment ensured, and unlikely that blinding could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding

Blinding of outcome assessment, but likely that blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

6.Blinding of outcome assessor (detection bias);

subjective outcomes

Low risk

Blinding of outcome assessment ensured, and unlikely that blinding could have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding

Blinding of outcome assessment, but likely that blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

7. Incomplete outcome data (attrition bias);

for all outcomes except retention in treatment or dropout

Low risk

No missing outcome data

Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias)

Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size

Missing data have been imputed using appropriate methods

All randomly assigned participants are reported/analysed in the group to which they were allocatedby randomisation, irrespective of non‐compliance and co‐interventions (intention to treat)

High risk

Reason for missing outcome data likely to be related to true outcome, with imbalance in numbers or reasons for missing data across intervention groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size

‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation

Unclear risk

Insufficient information to permit judgement of low or high risk (e.g. number randomised not stated, no reasons for missing data provided; number of dropouts not reported for each group)

8. Selective reporting (reporting bias)

Low risk

Study protocol is available, and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way

Study protocol is not available, but it is clear that published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon)

High risk

Not all of the study’s prespecified primary outcomes have been reported

One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified

One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect)

One or more outcomes of interest in the review are reported incompletely, so that they cannot be entered in a meta‐analysis

The study report fails to include results for a key outcome that would be expected to have been reported for such a study

Unclear risk

Insufficient information to permit judgement of low or high risk

original image
Figuras y tablas -
Figure 1

Study flow diagram of the updated version.
Figuras y tablas -
Figure 2

Study flow diagram of the updated version.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 4

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Any anticonvulsant versus placebo, Outcome 1 Dropout.
Figuras y tablas -
Analysis 1.1

Comparison 1 Any anticonvulsant versus placebo, Outcome 1 Dropout.

Comparison 1 Any anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).
Figuras y tablas -
Analysis 1.2

Comparison 1 Any anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).

Comparison 1 Any anticonvulsant versus placebo, Outcome 3 Side effect.
Figuras y tablas -
Analysis 1.3

Comparison 1 Any anticonvulsant versus placebo, Outcome 3 Side effect.

Comparison 1 Any anticonvulsant versus placebo, Outcome 4 Craving.
Figuras y tablas -
Analysis 1.4

Comparison 1 Any anticonvulsant versus placebo, Outcome 4 Craving.

Comparison 1 Any anticonvulsant versus placebo, Outcome 5 Severity of dependence (ASI).
Figuras y tablas -
Analysis 1.5

Comparison 1 Any anticonvulsant versus placebo, Outcome 5 Severity of dependence (ASI).

Comparison 1 Any anticonvulsant versus placebo, Outcome 6 Severity of dependence (CGI‐O).
Figuras y tablas -
Analysis 1.6

Comparison 1 Any anticonvulsant versus placebo, Outcome 6 Severity of dependence (CGI‐O).

Comparison 1 Any anticonvulsant versus placebo, Outcome 7 Depression (HAM‐D).
Figuras y tablas -
Analysis 1.7

Comparison 1 Any anticonvulsant versus placebo, Outcome 7 Depression (HAM‐D).

Comparison 1 Any anticonvulsant versus placebo, Outcome 8 Anxiety (HAM‐A).
Figuras y tablas -
Analysis 1.8

Comparison 1 Any anticonvulsant versus placebo, Outcome 8 Anxiety (HAM‐A).

Comparison 1 Any anticonvulsant versus placebo, Outcome 9 Compliance.
Figuras y tablas -
Analysis 1.9

Comparison 1 Any anticonvulsant versus placebo, Outcome 9 Compliance.

Comparison 1 Any anticonvulsant versus placebo, Outcome 10 Compliance.
Figuras y tablas -
Analysis 1.10

Comparison 1 Any anticonvulsant versus placebo, Outcome 10 Compliance.

Comparison 2 Single anticonvulsant versus placebo, Outcome 1 Dropout.
Figuras y tablas -
Analysis 2.1

Comparison 2 Single anticonvulsant versus placebo, Outcome 1 Dropout.

Comparison 2 Single anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).
Figuras y tablas -
Analysis 2.2

Comparison 2 Single anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).

Comparison 2 Single anticonvulsant versus placebo, Outcome 3 Side effects.
Figuras y tablas -
Analysis 2.3

Comparison 2 Single anticonvulsant versus placebo, Outcome 3 Side effects.

Comparison 3 Anticonvulsant (carbamazepine) vs antidepressant (desipramine), Outcome 1 Dropout.
Figuras y tablas -
Analysis 3.1

Comparison 3 Anticonvulsant (carbamazepine) vs antidepressant (desipramine), Outcome 1 Dropout.

Summary of findings for the main comparison. Any anticonvulsant versus placebo for cocaine dependence

Any anticonvulsant versus placebo for cocaine dependence

Patient or population: patients with cocaine dependence
Settings: outpatients
Intervention: any anticonvulsant versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Any anticonvulsant versus placebo

Dropout
Number of participants who did not complete the treatment
Follow‐up: mean 11.8 weeks1

45 per 100

42 per 100
(38 to 47)

RR 0.95
(0.86 to 1.05)

1695
(17 studies2)

⊕⊕⊕⊝
Moderate3,4

Use of cocaine (self reported or objective)
Number of participants who reported the use of cocaine during treatment, and/or number of participants with urine samples positive for cocaine
Follow‐up: mean 11.8 weeks1

77 per 100

71 per 100
(65 to 79)

RR 0.92
(0.84 to 1.02)

867
(9 studies5)

⊕⊕⊕⊝
Moderate6,7

Side effect
Number of participants reporting at least 1 side effect and types of side effects experienced during treatment
Follow‐up: mean 11.8 weeks1

46 per 100

65 per 100
(47 to 88)

RR 1.39
(1.01 to 1.9)

775
(8 studies)

⊕⊕⊝⊝
Low8,9

Craving (BSCS)
Measured by validated scales (e.g. Brief Substance Craving Scale (BSCS))
Follow‐up: mean 11.8 weeks1

The mean craving (bscs) in the intervention groups was
0.25 standard deviations lower
(0.59 lower to 0.09 higher)

428
(7 studies11)

⊕⊕⊝⊝
Low11,12,13

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.

GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Range 8 ‐ 24 weeks
2 20 treatment arms
3 In the Cornish 1995, Halikas 1997 arm a, Halikas 1997 arm b;Nuijten 2014, Umbricht 2014 studies an adequate sequence generation method was described and judged at low risk of selection bias. In the other 17 studies the method was not reported (unclear risk of bias). In five studies (Brodie 2009, Cornish 1995, Gonzalez 2007 arm a, Gonzalez 2007 arm b, Kranzler 1995, Umbricht 2014) an adequate method for allocation concealment was judged at low risk of selection bias. In all the other studies the method for allocation concealment was not reported (unclear risk of bias). Campbell 1994 arm was judged at high risk of selective reporting bias because results for drop out were not reported.
4 All the seventeen included studies were conducted in the USA
5 11 treatment arm
6 In the Cornish 1995, Halikas 1997 arm a, Halikas 1997 arm b;Nuijten 2014 studies an adequate sequence generation method was described and judged at low risk of selection bias. In the other studies the method was not reported (unclear risk of bias). In three studies (Brodie 2009, Cornish 1995, Gonzalez 2007 arm a, Gonzalez 2007 arm b) an adequate method for allocation concealment was judged at low risk of selection bias. In all the other studies the method for allocation concealment was not reported (unclear risk of bias). Nuijten 2014 were judged at high risk of performance bias and at unclear risk of detection bias All the other studies were judged at low risk of performance and detection bias. Cornish 1995, Halikas 1997 arm a, Halikas 1997 arm b, Kranzler 1995, Nuijten 2014 were judged at high risk of attrition bias.
7 I‐squared 30%
8 In the Brown 2012, Cornish 1995 and Nuijten 2014 studies an adequate sequence generation method was described and judged at low risk of selection bias. In the other studies the method was not reported (unclear risk of bias).One study was judged at high of bias ( Brown 2012) for allocation concealment. All the studies were judged at low risk of performance and detection bias. Brown 2012, Cornish 1995, Crosby 1996, Kranzler 1995, Nuijten 2014) were judged at high risk of attrition bias. All the other studies performed the analysis on the intention to treat basis or did not have withdrawn from the study.
9 I‐squared 81%
10 Eight treatment arms
11In the Nuijten 2014 studies an adequate sequence generation method was described and judged at low risk of selection bias. In the other studies the method was not reported (unclear risk of bias). In all the studies the method for allocation concealment was not reported (unclear risk of bias). Berger 2005 arm a, Berger 2005 arm b and Nuijten 2014 were judged at high risk of performance bias and at unclear risk of detection bias. Winhusen 2005 was judged at high risk both for performance and detection bias. Crosby 1996 and Nuijten 2014 were judged at high risk of attrition bias.
12I‐squared 63%
13 All the seven included studies were conducted in the USA

Figuras y tablas -
Summary of findings for the main comparison. Any anticonvulsant versus placebo for cocaine dependence
Comparison 1. Any anticonvulsant versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropout Show forest plot

20

1695

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.86, 1.05]

2 Use of cocaine (self reported or objective) Show forest plot

11

867

Risk Ratio (M‐H, Random, 95% CI)

0.92 [0.84, 1.02]

3 Side effect Show forest plot

8

775

Risk Ratio (M‐H, Random, 95% CI)

1.39 [1.01, 1.90]

3.1 New subgroup

8

775

Risk Ratio (M‐H, Random, 95% CI)

1.39 [1.01, 1.90]

4 Craving Show forest plot

8

428

Std. Mean Difference (IV, Random, 95% CI)

‐0.25 [‐0.59, 0.09]

5 Severity of dependence (ASI) Show forest plot

6

290

Mean Difference (IV, Random, 95% CI)

0.03 [‐0.02, 0.08]

6 Severity of dependence (CGI‐O) Show forest plot

5

277

Mean Difference (IV, Random, 95% CI)

‐0.11 [‐0.42, 0.20]

7 Depression (HAM‐D) Show forest plot

3

80

Mean Difference (IV, Random, 95% CI)

1.80 [‐0.59, 4.19]

8 Anxiety (HAM‐A) Show forest plot

3

78

Mean Difference (IV, Random, 95% CI)

1.79 [‐1.02, 4.60]

9 Compliance Show forest plot

6

343

Risk Ratio (M‐H, Random, 95% CI)

1.01 [0.93, 1.08]

10 Compliance Show forest plot

5

426

Mean Difference (IV, Random, 95% CI)

1.42 [‐4.80, 7.64]

Figuras y tablas -
Comparison 1. Any anticonvulsant versus placebo
Comparison 2. Single anticonvulsant versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropout Show forest plot

19

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Carbamazepine vs placebo

6

464

Risk Ratio (M‐H, Random, 95% CI)

0.99 [0.87, 1.13]

1.2 Tiagabine vs placebo

3

213

Risk Ratio (M‐H, Random, 95% CI)

1.01 [0.56, 1.82]

1.3 Gabapentin vs placebo

2

62

Risk Ratio (M‐H, Random, 95% CI)

2.78 [0.67, 11.61]

1.4 Phenytoin vs placebo

1

44

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.65, 1.35]

1.5 Lamotrigine vs placebo

1

23

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.11, 10.04]

1.6 Topiramate vs placebo

4

557

Risk Ratio (M‐H, Random, 95% CI)

0.92 [0.73, 1.16]

1.7 Vigabatrin vs placebo

2

289

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.53, 1.02]

2 Use of cocaine (self reported or objective) Show forest plot

12

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Carbamazepine vs placebo

4

214

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.70, 1.28]

2.2 Tiagabine vs placebo

1

50

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.61, 1.30]

2.3 Gabapentin vs placebo

2

146

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.87, 1.31]

2.4 Phenytoin vs placebo

1

12

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.05, 2.37]

2.5 Topiramate vs placebo

2

210

Risk Ratio (M‐H, Random, 95% CI)

1.19 [0.48, 2.98]

2.6 Vigabatrin vs placebo

2

289

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.69, 1.13]

3 Side effects Show forest plot

7

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 Carbamazepine vs placebo

2

122

Risk Ratio (M‐H, Random, 95% CI)

1.21 [0.52, 2.86]

3.2 Tiagabine vs placebo

0

0

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

3.3 Gabapentin vs placebo

1

95

Risk Ratio (M‐H, Random, 95% CI)

2.94 [0.62, 13.83]

3.4 Phenytoin vs placebo

1

44

Risk Ratio (M‐H, Random, 95% CI)

1.65 [0.83, 3.29]

3.5 Topiramate vs placebo

2

216

Risk Ratio (M‐H, Random, 95% CI)

2.42 [0.27, 21.87]

3.6 Vigabatrin vs placebo

1

186

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.88, 1.08]

Figuras y tablas -
Comparison 2. Single anticonvulsant versus placebo
Comparison 3. Anticonvulsant (carbamazepine) vs antidepressant (desipramine)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Dropout Show forest plot

1

96

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.86, 1.53]

Figuras y tablas -
Comparison 3. Anticonvulsant (carbamazepine) vs antidepressant (desipramine)